Her substantial response and prolonged benefit suggest that <i>BRAF</i>-mutated NSCLC may respond better than <i>EGFR</i>- or <i>ALK</i>-driven disease to immunotherapy. This evidence concerns the gene ALK and non-small cell lung carcinoma.